Climb Bio Inc (CLYM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$15.52+6.37%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CLYM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -36.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CLYM — director transition
Dated 2026-07-01
Director — Andrew Levin: Andrew Levin resigned as a director, and Breanna O'Reilly was elected to replace him.
Why it matters: Lower losses mean better cost control. This can boost investor trust.
Supportive ifOperating losses drop below $10M in the next quarter.
Worry ifOperating losses remain above $15M in the next quarter.
Why it matters: Data will show how CLYM116 is progressing in treating IgA nephropathy.
Supportive ifData for CLYM116 will be shared at the European Renal Association Congress in June 2026.
Worry ifNo data is presented at the ERA 2026 event.
Why it matters: Data from the SLE trial will help us see how budoprutug treats lupus. This disease affects the immune system.
Supportive ifInitial B-cell data from the global Phase 1b study is expected in Q4 2026.
Worry ifData shows no major B-cell loss or clinical improvement in SLE patients.
Why it matters: Updates will show how well the company manages its money. This is important as it advances its clinical programs.
Watch forCash runway goes beyond 2028. Operating expenses are stable.
Also watch forCash runway gets shorter. Operating expenses rise a lot.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$326 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $830 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,360 loss on $10,000 · 33.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on this partnership may show how CLYM116 and budoprutug are doing. Good news can help investor trust.
Supportive ifAnnouncement of successful patient dosing or data from the Phase 2 trial in China.
Worry ifNo updates or bad news about the partnership's progress.
Why it matters: Updates on cash runway will show the company's financial health. This affects investor trust.
Watch forManagement confirms cash runway extends into the second half of 2028.
Also watch forManagement changes cash runway guidance to a shorter time period.
Why it matters: High operating losses show problems with cost management. This may affect future funding.
Worry ifOperating losses reported at more than $15M for Q2 2026.
Less concerning ifOperating losses were less than $15M for Q2 2026.
Why it matters: Initial data from the ITP trial will show how well budoprutug works. This data is important for treating immune thrombocytopenia.
Supportive ifInitial B-cell and platelet data from the low dose cohort (250 mg at 24 weeks) is reported in June 2026.
Worry ifNo data is released. Results show no major B-cell loss or better platelet counts.
Why it matters: Starting the Phase 2 trial is a key milestone for CLYM116. It indicates progress in the drug's development and potential market entry.
Supportive ifManagement confirms that dosing in the Phase 2 trial of CLYM116 will begin in Q3 2026.
Worry ifThe trial does not start on time. This may cause delays in development.
Why it matters: Data from these trials will show how well budoprutug works. Good results could improve its market chance.
Watch forEarly data from budoprutug trials shows strong B-cell depletion. It also shows effectiveness.
Also watch forData shows low effectiveness and safety problems. This leads to a review of the trial.
Why it matters: Data from the pMN trial will show how well budoprutug works for kidney disease.
Supportive ifInitial B-cell and anti-PLA2R data from the low dose cohort (200 mg at 12-24 weeks) is expected in Q4 2026.
Worry ifData shows no major B-cell loss or clinical improvement in pMN patients.
Why it matters: Dosing the first patient in the China trial is a significant step for budoprutug's global development. It could open new markets.
Supportive ifFirst patient dosed in the China Phase 1b/2a trial of budoprutug.
Worry ifDelays in patient dosing or starting the trial may show problems. These could be regulatory or operational.
Why it matters: Initial data will show how well CLYM116 works in suppressing APRIL. This is key for its future in treating IgA nephropathy.
Supportive ifInitial Phase 1 data shows good APRIL suppression and safety. This was shared at the R&D Spotlight.
Worry ifInitial Phase 1 data is negative or unclear. It does not show strong APRIL suppression.
Why it matters: Updates will show how well budoprutug works for systemic lupus erythematosus. This may change its plans.
Watch forPositive updates show good B-cell depletion and better outcomes for patients in the SLE trial.
Also watch forUpdates show no big improvements or safety worries in the SLE trial.